InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.550 0.015 (2.80%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$150 Notification of cessation of securities - OCC 5 Jun 2024 8:26AM $0.365 $0.550 risen by 50.68%
$150 Outstanding 98.6% Success Rate in Striate Implant Study 14 May 2024 9:05AM $0.390 $0.550 risen by 41.03%
$150 Compelling 85% Success Rate Remplir Study now published 30 Apr 2024 9:49AM $0.380 $0.550 risen by 44.74%
$150 Change of Director's Interest Notice-John Van Der Wielen 24 Apr 2024 11:52AM $0.380 $0.550 risen by 44.74%
$150 Securities Trading Policy 24 Apr 2024 11:23AM $0.380 $0.550 risen by 44.74%
$150 Change of Director's Interest Notice-John Van Der Wielen 16 Apr 2024 8:56AM $0.385 $0.550 risen by 42.86%
$150 Orthocell receives $3.05m R&D tax incentive refund 15 Apr 2024 9:03AM $0.380 $0.550 risen by 44.74%
$150 Quarterly Activity Report & Appendix 4C 8 Apr 2024 9:03AM $0.415 $0.550 risen by 32.53%
$150 Part 1 Remplir US Market Authorisation Successfully Complete 25 Mar 2024 9:19AM $0.400 $0.550 risen by 37.50%
$150 Cleansing Notice 11 Mar 2024 6:06PM $0.400 $0.550 risen by 37.50%
$150 Application for quotation of securities - OCC 11 Mar 2024 6:05PM $0.400 $0.550 risen by 37.50%
$150 Application for quotation of securities - OCC 11 Mar 2024 6:04PM $0.400 $0.550 risen by 37.50%
$150 Cleansing Notice 28 Feb 2024 10:27AM $0.420 $0.550 risen by 30.95%
$150 Application for quotation of securities - OCC 28 Feb 2024 10:24AM $0.420 $0.550 risen by 30.95%
$150 Appendix 4D & Half-Year Financial Statements 23 Feb 2024 3:27PM $0.440 $0.550 risen by 25%
$150 Proposed issue of securities - OCC 22 Feb 2024 9:20AM $0.395 $0.550 risen by 39.24%
$150 Strategic Placement to Raise $3.5 million 22 Feb 2024 9:20AM $0.395 $0.550 risen by 39.24%
$150 Trading Halt 20 Feb 2024 9:43AM $0.395 $0.550 risen by 39.24%
$150 Remplir Expansion Continues with Singapore Application 13 Feb 2024 9:14AM $0.380 $0.550 risen by 44.74%
$150 Notification of cessation of securities - OCC 6 Feb 2024 8:15AM $0.375 $0.550 risen by 46.67%
$150 Quarterly Activity Report & Appendix 4C 29 Jan 2024 8:57AM $0.405 $0.550 risen by 35.80%
$150 Appendix 3Y - Kim Beazley 17 Jan 2024 2:14PM $0.410 $0.550 risen by 34.15%
$150 Notification regarding unquoted securities - OCC 17 Jan 2024 2:11PM $0.410 $0.550 risen by 34.15%
$150 Final Director's Interest Notice 16 Jan 2024 9:15AM $0.405 $0.550 risen by 35.80%
$150 Orthocell Board Changes 15 Jan 2024 4:50PM $0.405 $0.550 risen by 35.80%

226 - 250 of 775 results

Page 10 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.